Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Receivables - Other: 2015-2024

Historic Receivables - Other for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $3.6 million.

  • Syndax Pharmaceuticals' Receivables - Other rose 5.71% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 5.71%. This contributed to the annual value of $3.6 million for FY2024, which is 196.25% up from last year.
  • As of FY2024, Syndax Pharmaceuticals' Receivables - Other stood at $3.6 million, which was up 196.25% from $1.2 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Receivables - Other registered a high of $3.6 million during FY2024, and its lowest value of $175,000 during FY2020.
  • Its 3-year average for Receivables - Other is $2.8 million, with a median of $3.5 million in 2022.
  • Its Receivables - Other has fluctuated over the past 5 years, first skyrocketed by 709.79% in 2022, then tumbled by 64.68% in 2023.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Receivables - Other stood at $175,000 in 2020, then surged by 145.14% to $429,000 in 2021, then soared by 709.79% to $3.5 million in 2022, then crashed by 64.68% to $1.2 million in 2023, then spiked by 196.25% to $3.6 million in 2024.